UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007169
Receipt number R000008434
Scientific Title Pharmacokinetics test of pyridoxamine in uremic patients on peritoneal dialysis
Date of disclosure of the study information 2012/02/01
Last modified on 2015/01/31 11:06:25

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Pharmacokinetics test of pyridoxamine in uremic patients on peritoneal dialysis

Acronym

Pharmacokinetics of pyridoxiamine

Scientific Title

Pharmacokinetics test of pyridoxamine in uremic patients on peritoneal dialysis

Scientific Title:Acronym

Pharmacokinetics of pyridoxiamine

Region

Japan


Condition

Condition

End-stage renal disease

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To determine pharmacokinetics of oral pyridoxiamine in patients on peritoneal dialysis

Basic objectives2

Pharmacokinetics

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Pharmacokinetics of oral pyridoxiamine

Key secondary outcomes

Changes in carbonyl stress in the abdominal cavity and blood


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Oral pyridoxiamine 300-600 mg

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

Receiving maintenance peritoneal dialysis at least for 3 months
Not reiving vitamin B6 in the last 4 weeks

Key exclusion criteria

Receiving hemodialysis in addition to peritoneal dialysis
Severe liver disease or liver dysfunction
History of allergy or adverse effects to certain drugs
Participating in other clinical trials or received investigational products in the last 16 weeks
Having active cancers or received complete resection of cancers in the last 3 years
History of cardiovascular disease in the last 6 months
Receiving peritoneal dialysis for more than 8 years or having suspected encapsulating peritoneal sclerosis
Fontaine stage II peripheral arterial disease
Treatment resistant hypertension
Treatment resistant diabetes
Erythropoietin resistant anemia
Received aminophylline, theophylline, choline theophylline, or levodopa in the last 4 weeks
Pregnant women or those intending to become pregnant during the next 1 year

Target sample size

6


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takatoshi Kakuta

Organization

Tokai University School of Medicine

Division name

Division of Nephrology, Endocrinology and Metabolism

Zip code


Address

143 Shimo-Kasuya, Isehara, 259-1193, Japan

TEL

0463-93-1121

Email

kakuta@is.icc.u-tokai.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takatoshi Kakuta

Organization

Tokai University School of Medicine

Division name

Division of Nephrology, Endocrinology and Metabolism

Zip code


Address

143 Shimo-Kasuya, Isehara, 259-1193, Japan

TEL

0463-93-1121

Homepage URL


Email

kakuta@is.icc.u-tokai.ac.jp


Sponsor or person

Institute

Tokai University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

The Health and Labour Sciences Research Grant on Intractable Diseases

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 02 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 12 Month 01 Day

Date of IRB


Anticipated trial start date

2012 Year 02 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 01 Month 30 Day

Last modified on

2015 Year 01 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008434


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name